<DOC>
	<DOC>NCT01439984</DOC>
	<brief_summary>The purpose of this study is to evaluate whether PED-1 is more effective than Placebo in the treatment of premature ejaculation.</brief_summary>
	<brief_title>Trial of PED-1 in Male Patients With Premature Ejaculation</brief_title>
	<detailed_description>This study is to evaluate whether PED-1 is effective than Placebo in the treatment of premature ejaculation. The patients will be randomized and allocated to two treatment groups into placebo, PED-1. The criteria for Intravaginal Ejaculation Latency Time(IELT) for enrollment will be &gt; or =2 min in the at least 75% of the sexual intercourse. To diagnosis premature ejaculation, the PEDT(Premature Ejaculation Diagnosis Tool) will be used. The patients undergone drug free baseline period will take test drugs for 12 weeks.</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>Clomipramine</mesh_term>
	<criteria>Informed consent for subjects and partners Men 2065 ages Stable monogamous relation at least for 6 mo Premature Ejaculation Diagnosis Tool (PEDT) more than 9 At least 6 mo of premature ejaculation Hx IELT of =&lt; 2 min in &gt;= 75% of evaluable events during 4 week screening period History of medical or psychiatric illness Erectile dysfunction (&lt;21 International Index of Erectile FunctionErectile Function (IIEFEF) domain score) or other forms of sexual dysfunction Partner sexual dysfunction Known hypersensitivity to clomipramine and contraindications for clomipramine</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PE</keyword>
	<keyword>IELT</keyword>
	<keyword>DCIT</keyword>
</DOC>